This open basket study aims to compare the safety and efficacy of durvalumab in combination with the PARPi olaparib or in combination with olaparib plus the VEGF inhibitor bevacizumab in patients with advanced solid tumors including BRCA1/2-deficient breast cancer. This evidence concerns the gene BRCA1 and breast cancer.